All posts by WordPress PHRI.ICT

John - Studies Post

PIAAF – Pharmacy

Leave a comment

Program for the Identification of “Actionable” Atrial Fibrillation (PIAAF): In the Pharmacy Setting

Along with screening for AF, participants in this study will also be screened for hypertension (high blood pressure) and diabetes.  Studies have shown that a person will visit a pharmacy five-times more often than any other healthcare provider. Pharmacists are the third largest group of health professionals in Canada. They are highly accessible, and often the first point of entry in the healthcare system and an essential link between patients and other healthcare providers.
PIAAF-Pharmacy

John - Studies Post

ASSERT III

Prevalence of Sub-Clinical Atrial Fibrillation in Elderly Patients With Hypertension, Detected Using an External Loop Recorder

Patients in the ASSERT III study will be monitored over a 60 day period for the development of subclinical AF via an external loop recorder. The device will automatically record and transmit ECGs through a BlackBerry Smartphone. The primary hypothesis is that among this elderly population with hypertension and a least one other risk factor for AF, the monitoring will detect AF in at least 10% of patients who would be potential candidates for anticoagulant therapy.
ASSERT III – ClinicalTrials.gov

John - Studies Post

STROKESTOP II

Systematic NT-proBNP and ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm, Sweden

The STROKESTOP II study is a proposed study to determine if the biomarker NT-proBNP together with single-lead ECG can be used as a primary population screening tool for silent atrial fibrillation, and builds on previous results from the STROKESTOP study.
https://clinicaltrials.gov/ct2/show/NCT02743416?term=STROKESTOP&rank=1
http://www.strokestop2.se

John - Studies Post

STROKESTOP

Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden

The aims of the present study were to define the prevalence of untreated atrial fibrillation (AF) in a systematic screening program using intermittent ECG recordings among 75- to 76-year-old individuals and to study the feasibility of initiating protective oral anticoagulant (OAC) treatment.
STROKESTOP – ClinicalTrials.gov

2020, Virtual

Virtual – International Collaboration Meeting

Friday September 25, 2020

Co-chairs
Ben Freedman
Emma Svennberg         		CLOSED SESSION FOR AF-SCREEN MEMBERS AND INDUSTRY SUPPORTERS
Zoom Session
Request Password
Ben Freedman Welcome and introduction              
Lena Rivard Dementia and AF Screening White paper
Emma Svennberg      Progress of ongoing large screening studies with hard outcome endpoints
Jeff Healey Meta-analysis and meta-regression of studies with hard endpoints: Status of Prospero Paper
Giuseppe Boriani Survey: wearables/devices and consumer-led screening
Axel Brandes 
Stavros Stavrakis  		Consumer-led AF Screening White paper
Renate Schnabel AF-SCREEN Future Activities and Horizon 2020/AFFECT-EU programme update
Co-Chairs
Jeff Healey
Renate Schnabel                		 OPEN SESSION ON AF SCREENING
MP4
4.7 GB download
Ben Freedman Year in Review for AF-SCREEN and Screening for AF
Mike Gibson Heartline study update (Janssen J&J/Bayer/Apple watch)
Søren Diederichsen Simulations from the Danish Loop Study: relevance to other screening methodologies
Peter Noseworthy AI and Machine Learning using eMR, biomarkers and 12-lead ECG to predict AF and AF-related events
Emelia Benjamin What are the research priorities in screening for AF

Thank you to our supportive sponsors:

    2018, 2018 Munich, Meetings, Munich

    2018 Munich – Annual Meeting

    Saturday, August 25, 2018

    Ben Freedman Year in review: Screening for Atrial Fibrillation
    Mårten Rosenqvist Update on current and planned outcome studies
    Jonathan Mant Status of UK primary care screening study
    John Eikelboom Covert AF in Vascular Prevention Trials:  Lessons from COMPASS and NAVIGATE ESUS – [download will be available early 2019]
    Barbara Casadei UK Biobank study
    Jeff Healey Treatment of subclinical AF
    Renate Schnabel
    Ben Freedman    		 Controversies and key points for post-stroke white paper
    Mintu Turakhia Testing new AF screening methods at scale – [slides not available – more information is available at this link]
    Ben Freedman Future activities and meetings